Implications of BCR-ABL1 kinase domain-mediated resistance in chronic myeloid leukemia

被引：138
|
作者：
Soverini, Simona [1 ]
Branford, Susan [2 ,3 ,4 ]
Nicolini, Franck E. [1 ,5 ]
Talpaz, Moshe
Deininger, Michael W. N. [6 ]
Martinelli, Giovanni [1 ]
Mueller, Martin C. [7 ]
Radich, Jerald P. [8 ]
Shah, Neil P. [9 ]
机构：
[1] Univ Bologna, S Orsola Malpighi Hosp, Dept Expt Diagnost & Specialty Med, Bologna, Italy
[2] SA Pathol, Dept Mol Pathol, Ctr Canc Biol, Adelaide, SA, Australia
[3] Univ Adelaide, Sch Med, Adelaide, SA, Australia
[4] Univ Adelaide, Sch Mol & Biomed Sci, Adelaide, SA, Australia
[5] Ctr Hosp Lyon Sud, Hematol Dept 1G, F-69310 Pierre Benite, France
[6] Univ Michigan, Dept Internal Med, Div Hematol & Oncol, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA
[7] Heidelberg Univ, Med Klin 3, Univ Med Mannheim, Mannheim, Germany
[8] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[9] Univ Calif San Francisco, Dept Hematol Oncol, San Francisco, CA 94143 USA
来源：
LEUKEMIA RESEARCH | 2014年 / 38卷 / 01期
关键词：
BCR-ABL1; Kinase domain; Tyrosine kinase inhibitors; Philadelphia chromosome; Chronic myeloid leukemia; Resistance; Mutations; DIAGNOSED CHRONIC-PHASE; BCR-ABL MUTATIONS; DASATINIB; 100; MG; PHILADELPHIA-POSITIVE PATIENTS; GIMEMA WORKING PARTY; IMATINIB-RESISTANT; FOLLOW-UP; HIGH-RISK; CML; CHROMOSOME;
D O I：
10.1016/j.leukres.2013.09.011
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Patients with chronic myeloid leukemia develop resistance to both first-generation and second-generation tyrosine kinase inhibitors (TKIs) as a result of mutations in the kinase domain (KD) of BCR-ABL1. A wide range of BCR-ABL1 KD mutations that confer resistance to TKIs have been identified, and the T3151 mutant has proven particularly difficult to target. This review summarizes the prevalence impact, and prognostic implications of BCR-ABL1 KD mutations in patients with chronic myeloid leukemia who are treated with current TKIs and provides an overview of recent treatment guidelines and future trends for the detect of mutatkins. (C) 2013 The Authors. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码：10 / 20
页数：11
相关论文
共 50 条
  • [31] Molecular analysis of the BCR-ABL1 kinase domain in chronic-phase chronic myelogenous leukemia treated with tyrosine kinase inhibitors in practice: Study by the Nagasaki CML Study Group
    Itonaga, Hidehiro
    Tsushima, Hideki
    Imanishi, Daisuke
    Hata, Tomoko
    Doi, Yuko
    Mori, Sayaka
    Sasaki, Daisuke
    Hasegawa, Hiroo
    Matsuo, Emi
    Nakashima, Jun
    Kato, Takeharu
    Horai, Makiko
    Taguchi, Masataka
    Matsuo, Masatoshi
    Taniguchi, Hiroaki
    Makiyama, Junnya
    Sato, Shinya
    Horio, Kensuke
    Ando, Koji
    Moriwaki, Yuji
    Sawayama, Yasushi
    Ogawa, Daisuke
    Yamasaki, Reishi
    Takasaki, Yumi
    Imaizumi, Yoshitaka
    Taguchi, Jun
    Kawaguchi, Yasuhisa
    Yoshida, Shinichiro
    Joh, Tatsuro
    Moriuchi, Yukiyoshi
    Nonaka, Hiroaki
    Soda, Hisashi
    Fukushima, Takuya
    Nagai, Kazuhiro
    Kamihira, Shimeru
    Tomonaga, Masao
    Yanagihara, Katsunori
    Miyazaki, Yasushi
    LEUKEMIA RESEARCH, 2014, 38 (01) : 76 - 83
  • [32] Comment on "Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors"
    Kim, Sung-Hyun
    Kim, Dong-Wook
    HAEMATOLOGICA, 2015, 100 (03) : E120 - E121
  • [33] Advances in treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: the evolving role of Bcr-Abl mutations and mutational analysis
    Soverini, Simona
    Martinelli, Giovanni
    Rosti, Gianantonio
    Iacobucci, Ilaria
    Baccarani, Michele
    PHARMACOGENOMICS, 2012, 13 (11) : 1271 - 1284
  • [34] Primary imatinib resistance in chronic myeloid leukemia patients in a developing country: BCR-ABL kinase domain mutations or BCR-ABL independent mechanisms?
    Yap, E.
    Tumian, N. R.
    Azma, R. Z.
    Sharifah, N. A.
    Salwati, S.
    Hamidah, N. H.
    Elias, M. H.
    Wong, C. L.
    MALAYSIAN JOURNAL OF PATHOLOGY, 2017, 39 (02) : 107 - 113
  • [35] ABL1 tyrosine kinase domain mutations in chronic myeloid leukemia treatment resistance
    Vacarean-Trandafir, Irina Cezara
    Ivanov, Iuliu Cristian
    Dragos, Loredana Mihaiela
    Dascalescu, Angela Smaranda
    Titieanu, Amalia Andrea
    Cojocaru, Dumitru
    MOLECULAR BIOLOGY REPORTS, 2019, 46 (04) : 3747 - 3754
  • [36] Detection of BCR-ABL kinase domain mutations in patients with chronic myeloid leukemia on imatinib
    Chahardouli, Bahram
    Zaker, Farhad
    Mousavi, Seied Asadollah
    Saffari, Zeinab
    Nadali, Fatemeh
    Ostadali, Mohammadreza
    Ghadimi, Habibeh
    Alimoghaddam, Kamran
    Ghavamzade, Ardeshir
    Rostami, Shahrbano
    HEMATOLOGY, 2013, 18 (06) : 327 - 332
  • [37] Mechanisms of Cardiovascular Toxicity of BCR-ABL1 Tyrosine Kinase Inhibitors in Chronic Myelogenous Leukemia
    Gustafson, Dakota
    Fish, Jason E.
    Lipton, Jeffrey H.
    Aghel, Nazanin
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2020, 15 (01) : 20 - 30
  • [38] Navigating Challenges in Monitoring Chronic Myeloid Leukemia with Multiple BCR-ABL1 Transcripts
    Smith, Brittany M.
    Brewer, Diana
    Druker, Brian J.
    Braun, Theodore P.
    CASE REPORTS IN ONCOLOGY, 2021, 14 (03): : 1707 - 1711
  • [39] Prognostic Significance of Transcript-Type BCR-ABL1 in Chronic Myeloid Leukemia
    Molica, Matteo
    Abruzzese, Elisabetta
    Breccia, Massimo
    MEDITERRANEAN JOURNAL OF HEMATOLOGY AND INFECTIOUS DISEASES, 2020, 12
  • [40] Frequency of rare BCR-ABL1 fusion transcripts in chronic myeloid leukemia patients
    Arun, A. K.
    Senthamizhselvi, A.
    Mani, S.
    Vinodhini, K.
    Janet, N. B.
    Lakshmi, K. M.
    Abraham, A.
    George, B.
    Srivastava, A.
    Srivastava, V. M.
    Mathews, V.
    Balasubramanian, P.
    INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2017, 39 (03) : 235 - 242
12345